VIVANI MEDICAL ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SLIM-1™, A FIRST IN HUMAN PHASE 1 TRIAL OF NPM-139 (SEMAGLUTIDE IMPLANT) AND WEGOVY
VIVANI MEDICAL ANNOUNCES POSITIVE TOP-LINE RESULTS FROM SLIM-1™, A FIRST IN HUMAN PHASE 1 TRIAL OF N
Story updates
01:02:32 PM UTC
SquawkNews
Vivani reported SLIM-1 Phase 1 results: 0 of 10 NPM-139 participants had treatment-related adverse events, and weight loss was 0.79% versus 0.82% for Wegovy. The company plans a Phase 2 dose-ranging weight-maintenance trial, anticipated to begin in 2027.Material DetailsContext by AI AnalystThis is…